Alcon Inc. (SWX:ALC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 28.20B -3.4% |
| Revenue (ttm) | 9.16B +7.8% |
| Net Income | 555.67M -36.4% |
| EPS | 1.14 -34.7% |
| Shares Out | 483.40M |
| PE Ratio | 51.03 |
| Forward PE | 19.57 |
| Dividend | 0.28 (0.48%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,218,046 |
| Open | 57.10 |
| Previous Close | 61.88 |
| Day's Range | 56.26 - 58.90 |
| 52-Week Range | 47.80 - 68.34 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 74.46 (+27.63%) |
| Earnings Date | Nov 11, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS... [Read more]
Financial Performance
In 2025, Alcon's revenue was $10.40 billion, an increase of 4.94% compared to the previous year's $9.91 billion. Earnings were $980.00 million, a decrease of -3.73%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is CHF 74.46, which is an increase of 27.63% from the latest price.
News
Alcon Earnings release: Q3 2026
Alcon released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
Alcon Slides: Q3 2026
Alcon has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 11, 2026.
Alcon Quarterly report: Q3 2026
Alcon has published its Q3 2026 quarterly earnings report on November 11, 2026.
Alcon shares fall as tighter eye-care market outlook raises growth concerns
Alcon shares fall as tighter eye-care market outlook raises growth concerns
Alcon Q3 Profit Rises 10%; Tightens FY26 Outlook
(RTTNews) - Alcon Inc. (ALC), an eye care company offering surgical and vision care products, on Tuesday reported an increase in profit and revenues for the third quarter, driven largely by growth acr...
Alcon reports Q3 EPS 91c, consensus 89c
Reports Q3 revenue $2.71B, consensus $2.74B. “We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas…
Alcon narrows FY26 EPS growth view to 12%-14% from 12%-15%
Consensus $3.50. Narrows FY26 revenue growth view to 6% from up 5%-7%, consensus $11.08B.
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
GENEVA--(BUSINESS WIRE)--Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth.
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RxSight, Inc. Reports Third Quarter 2026 Financial Results
RxSight, Inc. reported total revenue of $24.6 million for the third quarter ended September 30, 2026, down 19% from the prior-year period, primarily reflecting ongoing competitive pressures. Revenue r...
Alcon price target lowered to $84 from $88 at KeyBanc
KeyBanc lowered the firm’s price target on Alcon (ALC) to $84 from $88 and keeps an Overweight rating on the shares. While the firm remains confident in visibility toward Alcon’s…
Alcon acquires Neurotech and expands retina portfolio with ENCELTO
Alcon (ALC) announced it has acquired Neurotech Pharmaceuticals, a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alco...
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.
Alcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye Drops
(RTTNews) - Alcon (ALC, ALC.SW) announced that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, an over-the-counter treatment designed to reduce eye redness.
Alcon announces FDA approval of Brytly Redness Reliever Eye Drops
Alcon (ALC) announced that the U.S. FDA has approved Brytly Redness Reliever Eye Drops. With one drop, Brytly works in just one minute to significantly reduce redness and delivers up…
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
One drop works to significantly reduce redness, with results lasting up to 12 hours1 Lasts up to 50% longer than Lumify1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be av...
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
Alcon price target lowered to $80 from $85 at Mizuho
Mizuho lowered the firm’s price target on Alcon (ALC) to $80 from $85 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and…
Alcon price target lowered to $74 from $82 at BTIG
BTIG lowered the firm’s price target on Alcon (ALC) to $74 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Alcon initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Alcon (ALC) with an Equal Weight rating and $70 price target The firm rolled out coverage of the medical suppliers and devices group…
Introducing Systane PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of Systane PRO Preservative-Free (PF) in Canada as Systane’s most advanced formula. Systane...
Alcon Becomes Oversold (ALC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Alcon price target lowered to $85 from $95 at Jefferies
Jefferies analyst Michael Sarcone lowered the firm’s price target on Alcon (ALC) to $85 from $95 and keeps a Buy rating on the shares. The ophthalmology sector has been under…
Alcon announces initial commercial launch of UNITY M
Alcon (ALC) announced the initial commercial launch of UNITY M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the U.S. an...